Ignite Creation Date:
2024-05-05 @ 11:33 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01351103
Status:
COMPLETED
Last Update Posted:
2024-05-30
First Post:
2011-05-04
Brief Title:
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase I Open-label Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite standard therapy or for which no effective standard therapy existed
Detailed Description:
This open-label multicenter phase 1 dose escalation study was the first to administer LGK974 as a single agent or in combination with PDR001 in humans
The study comprised of 2 parts a dose escalation of LGK974 as a single agent followed by a safety expansion in specific disease indications and a dose escalation of LGK974 in combination with PDR001 followed by a safety expansion in cutaneous melanoma
The study comprised of 2 parts a dose escalation of LGK974 as a single agent followed by a safety expansion in specific disease indications and a dose escalation of LGK974 in combination with PDR001 followed by a safety expansion in cutaneous melanoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-000495-33 | EUDRACT_NUMBER | None | None |